Published Online: January 9, 2023. doi:10.1001/jamaneurol.2022.4861
Correction: This article was corrected on March 13, 2023, to fix a misspelling in the surname of the second author, Vergil Mavrodiev.
Corresponding Author: Michael Strupp, MD, University of Munich, Marchioninistrasse 15, Munich 81377, Germany (firstname.lastname@example.org).
Conflict of Interest Disclosures: Dr Strupp reported speaker’s honoraria from Abbott, Actelion, Auris Medical, Biogen, Eisai, Grünenthal, GSK, Henning Pharma, Interacoustics, Johnson & Johnson, Merck, MSD, NeuroUpdate, Otometrics, Pierre-Fabre, TEVA, UCB, and Viatris; grants from Decibel Therapeutics, Cures Within Reach, and Heel; consulting fees from Abbott, Actelion, AurisMedical, Bulbitec, Heel, IntraBio, Sensorion, and Vertify; and a patent as an investor and shareholder of IntraBio and licensed patents for Acetyl-DL-leucine. He is Joint Chief Editor of the Journal of Neurology, Editor in Chief of Frontiers of Neuro-otology, and Section Editor of F1000 and distributes M-glasses and the positional vertigo app. Dr Goldschagg reported personal fees from IntraBio. No other disclosures were reported.
Additional Contributions: We thank the patient and videographer for granting permission to publish this information.